What amount sold does Axxess Compounding LLLP report in Form D filings?

The latest linked filings report $458K sold across 1 identified offering(s). 0 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was Axxess Compounding LLLP's most recent SEC filing?

Axxess Compounding LLLP's most recent Form D filing was on 2014-11-07.

How many investors does Axxess Compounding LLLP have?

The most recent Form D filing lists 34 investor(s).

What type of securities does Axxess Compounding LLLP offer?

Axxess Compounding LLLP's SEC Form D filings indicate equity offerings.

Axxess Compounding LLLP

CIK: 0001584530·Pharmaceuticals·PACIFIC PALISADES, CA·Limited Partnership·Founded 2011

Reported Sold

$457,500

Total Filings

Identified Offerings

Last Filed

Nov 7, 2014

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately.

About

Company in Pharmaceuticals industry

SEC EDGAR

Offering filing timeline

Nov 7, 2014Form D/A — Amendment

Reported sold: $457,500 · Target: $25,000,000

Rule 506(b)·34 investors

Changed: Reported amount sold, Offering target, Reported investors

Jan 9, 2014Form D/A — Amendment

Reported sold: $240,000 · Target: $690,000

Rule 506(b)·3 investors

Changed: Reported amount sold, Offering target, Exemptions

Aug 16, 2013Form D — New notice

Reported sold: $25,000 · Target: $470,000

Rule 506·3 investors

Fundraising Profile

Exemptions

Rule 506(b)

Investors in latest filing

Revenue Range

No Revenues

Reported commissions across identified offerings

Amendment Rate

67%

Latest reported sold across 1 identified offering

$457,500

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

Key People

Francis X Riegler

Related Person

Appears on 3 filings

Filing History

Date	Type	Offering target	Reported sold	Investors
Nov 7, 2014	Amendment	$25,000,000	$457,500	34
Jan 9, 2014	Amendment	$690,000	$240,000	3
Aug 16, 2013	New	$470,000	$25,000	3

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

CeleCor Therapeutics, Inc.

Pharmaceuticals

Offering target: $15,000,000

Filed Jul 9, 2026